API
< Back to all clusters
[BUSINESS] · Germany · 2 sources

started · updated

Evotec receives $2.9 million from Gates Foundation

Evotec has been awarded a $2.9 million grant from the Gates Foundation to extend a project focused on using human stem cell technology to identify safety risks in drug candidates. The funding extends a project initiated in 2023 for an additional three years.

The company utilizes human induced pluripotent stem cells (hiPSC) and automated high-throughput screening to detect teratogenicity, which refers to substances that interfere with embryonic development. Since 2023, the platform has screened more than 5,000 substances across nine funding programs to determine if they could harm an unborn fetus.

This technology allows global health researchers to assess potential developmental risks earlier in the drug discovery process. By modeling human development through cell behavior, researchers can make more informed decisions about which drug candidates to advance into clinical testing, potentially reducing the need for later changes in course.

Entities

Evotec · Gates Foundation